Literature DB >> 9618803

Insulin-like growth factor-I and -II in human benign prostatic hyperplasia: relationship with binding proteins 2 and 3 and androgens.

S Monti1, F Di Silverio, S Lanzara, P Varasano, C Martini, C Tosti-Croce, F Sciarra.   

Abstract

In prostatic tissue, androgen action may be mediated by growth factors such as insulin-like growth factor-I (IGF-I) and II (IGF-II), which are mitogenic for prostatic cells and modulate the stroma-epithelium interaction. IGF-binding proteins (IGFBPs) have an autocrine and/or paracrine role in regulating the local actions of the IGFs. In this study, testosterone, dihydrotestosterone (DHT), 3 alpha androstanediol (3 alpha diol), IGF-I, IGF-II, IGFBP2, and IGFBP3 concentrations were evaluated in human benign prostatic hyperplasia (BPH) tissue. Samples of prostate tissue were removed by suprapubic prostatectomy from twelve BPH patients. Androgen tissue levels were determined by radioimmunoassay after purification on celite microcolumns. IGF-I, IGFBP2, and IGFBP3 were measured by radioimmunoassay, and IGF-II by immunoradio metric assay, after acidification and chromatography on Sep-pak C18 Cartridges for IGF-I and IGF-II. Androgen concentrations, expressed in ng/g tissue (mean +/- SE), were 0.51 +/- 0.05 for testosterone, 5.3 +/- 0.16 for DHT, and 1.1 +/- 0.07 for 3 alpha diol. IGF-I, IGF-II, IGFBP2, and IGFBP3 levels were 24 +/- 3.7, 121 +/- 14 ng/g tissue and 0.44 +/- 0.05 and 1.2 +/- 0.17 micrograms/g tissue, respectively. No correlation between IGF-I, androgens, and IGFBPs was found. IGF-II was positively correlated with DHT (r = 0.78; p = 0.003) and 3 alpha diol (r = 0.66; p = 0.021) but not with IGFBPs. These data suggest that in BPH, DHT modulates the IGF system by increasing IGF-II without modifying IGFBPs. Therefore, the stroma-epithelium interaction, which plays an important role in prostatic growth, may be regulated by DHT through IGF-II.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9618803     DOI: 10.1016/s0039-128x(98)00034-8

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  6 in total

1.  Overexpression of IGBFB2 is a marker for malignant transformation in prostate epithelium.

Authors:  Elin Richardsen; Tanja Ukkonen; Tone Bjørnsen; Elin Mortensen; Lars Egevad; Christer Busch
Journal:  Virchows Arch       Date:  2003-04-01       Impact factor: 4.064

2.  Metabolic factors associated with benign prostatic hyperplasia.

Authors:  J Kellogg Parsons; H Ballentine Carter; Alan W Partin; B Gwen Windham; E Jeffrey Metter; Luigi Ferrucci; Patricia Landis; Elizabeth A Platz
Journal:  J Clin Endocrinol Metab       Date:  2006-04-11       Impact factor: 5.958

3.  Prostate size correlates with fasting blood glucose in non-diabetic benign prostatic hyperplasia patients with normal testosterone levels.

Authors:  Won Tae Kim; Seok Joong Yun; Young Deuk Choi; Gi-Young Kim; Sung-Kwon Moon; Yung Hyun Choi; Isaac Yi Kim; Wun-Jae Kim
Journal:  J Korean Med Sci       Date:  2011-09-01       Impact factor: 2.153

4.  Expression of the insulin-like growth factor (IGF) system and steroidogenic enzymes in canine testis tumors.

Authors:  Monique A J Peters; Jan A Mol; Monique E van Wolferen; Marja A Oosterlaken-Dijksterhuis; Katja J Teerds; Frederik J van Sluijs
Journal:  Reprod Biol Endocrinol       Date:  2003-02-14       Impact factor: 5.211

5.  Linking pre-diabetes with benign prostate hyperplasia. IGFBP-3: a conductor of benign prostate hyperplasia development orchestra?

Authors:  Ioannis Protopsaltis; Achilles Ploumidis; Theodoros N Sergentanis; Padelis Constantoulakis; Kostantinos Tzirogiannis; Chrysoula Kyprianidou; Athanasia K Papazafiropoulou; Andreas Melidonis; Dimitrios Delakas
Journal:  PLoS One       Date:  2013-12-19       Impact factor: 3.240

Review 6.  Emerging Roles for Browning of White Adipose Tissue in Prostate Cancer Malignant Behaviour.

Authors:  Alejandro Álvarez-Artime; Belén García-Soler; Rosa María Sainz; Juan Carlos Mayo
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.